Non-Hodgkin lymphoma (NHL) represents a diverse group of blood cancers that originate in the lymphatic system, particularly in lymphocytes, which are crucial for the immune response. The condition is characterized by the uncontrolled proliferation of abnormal lymphocyte cells, leading to a variety of symptoms and complications. NHL can vary widely in its aggressiveness, with some types being indolent (slow-growing) and others aggressive (fast-growing), and it can occur at any age, though incidence generally increases with age.

Several factors can increase the risk of developing Non-Hodgkin lymphoma, including age, with the likelihood rising significantly after age 60. Additional risk factors include a weakened immune system, certain autoimmune diseases such as rheumatoid arthritis or lupus, and a history of organ transplant. Exposure to certain chemicals, such as pesticides and solvents, as well as viral infections like HIV, Epstein-Barr virus, and hepatitis C, are also associated with an elevated risk of developing NHL.

The symptoms of Non-Hodgkin lymphoma may vary based on the subtype and progression of the disease, but common signs include swollen lymph nodes, unexplained fever, weight loss, night sweats, and persistent fatigue. Patients may also experience abdominal pain or swelling, frequent infections, and skin rashes. These symptoms can often be mistaken for other conditions, making an accurate diagnosis critical.

Non-Hodgkin lymphoma (NHL) arises from abnormal growth of lymphocytes, a type of white blood cell integral to the immune system. While the exact cause of NHL remains largely unknown, several risk factors have been identified, including age, genetic predisposition, prior infections with certain viruses (such as Epstein-Barr virus), and exposure to specific chemicals like pesticides and solvents. Immunosuppression, whether due to medications or conditions such as HIV/AIDS, also increases the likelihood of developing this cancer.

The diagnosis of Non-Hodgkin lymphoma typically begins with a thorough medical history and physical examination, followed by imaging studies such as CT scans or PET scans to assess the extent of disease. A definitive diagnosis usually requires a biopsy of the affected lymph node or tissue, which is then examined histologically for the presence of malignancy. Blood tests may also be conducted to evaluate overall health and organ function, alongside specific tests for biomarkers that can help define the specific subtype of NHL.

The treatment for non-Hodgkin lymphoma depends on the specific subtype, stage of the disease, and the patient's overall health. Common approaches include chemotherapy, immunotherapy, targeted therapy, and radiation therapy. In some cases, stem cell transplantation may be considered for eligible patients, particularly those with aggressive forms of NHL. Continuous monitoring and follow-up are essential to assess the effectiveness of treatment and manage any potential side effects.

While there is no guaranteed way to prevent Non-Hodgkin lymphoma, individuals can reduce their risk by maintaining a healthy lifestyle, which includes a balanced diet, regular physical activity, and avoiding known carcinogens such as tobacco and excessive pesticides. Additionally, taking measures to support a robust immune system, such as managing autoimmune conditions and avoiding infections with known oncoviruses, can potentially lower risk. Regular check-ups with healthcare providers can also assist in early detection and timely intervention if necessary.